RecruitingPHASE1, PHASE2NCT05268237

Safety, Tolerability and Preliminary Efficacy of Sublingual Liraglutide in Patients With Type 2 Diabetes Mellitus

Studying MODY

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Biolingus
Principal Investigator
Elaine YK Chow
Chinese University of Hong Kong
Intervention
Liraglutide(drug)
Enrollment
15 target
Eligibility
18-65 years · All sexes
Timeline
20232026

Study locations (1)

Collaborators

Chinese University of Hong Kong

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05268237 on ClinicalTrials.gov

Other trials for MODY

Additional recruiting or active studies for the same condition.

See all trials for MODY

← Back to all trials